Previous Close | $395.28 |
Intrinsic Value | $8.47 |
Upside potential | -98% |
Data is not available at this time.
Stryker Corporation operates as a leading medical technology company, specializing in orthopedic implants, surgical equipment, and neurotechnology solutions. The company generates revenue through a diversified portfolio of high-margin products, including joint replacements, trauma devices, and advanced surgical navigation systems. Its business model relies on innovation-driven R&D, strategic acquisitions, and a global distribution network, positioning it as a key player in the $400B+ medtech industry. Stryker maintains a competitive edge through its focus on minimally invasive technologies, robotics (e.g., Mako system), and digital healthcare integration, catering to hospitals and ASCs worldwide. The company holds top-three market positions in orthopedics and neurovascular segments, benefiting from aging demographics and procedural volume growth. Its MedSurg segment provides steady cash flows, while its higher-growth Orthopaedics and Spine/Neurotechnology divisions drive margin expansion.
Stryker reported $22.6B in FY2024 revenue, demonstrating mid-single-digit organic growth across its segments. Net income reached $3.0B (13.2% margin), with diluted EPS of $7.76. Operating cash flow of $4.2B reflects strong working capital management, though capital expenditures of $755M indicate ongoing investments in manufacturing automation and robotics platforms. The company's gross margins remain industry-leading at ~65%, supported by premium pricing and product mix.
The company generates robust ROIC of ~15%, exceeding its WACC, through disciplined capital allocation to high-growth segments like robotic surgery. Operating leverage is evident as SG&A expenses (32% of sales) decline with scale. Stryker's $3.2B in annual R&D spend (14% of sales) fuels a pipeline with 50+ active clinical trials, ensuring future earnings durability in high-ASP product categories.
Stryker maintains $3.7B in cash against $13.6B of total debt, with a manageable net leverage ratio of 2.3x EBITDA. The balance sheet supports continued M&A activity, as evidenced by recent tuck-in acquisitions. Liquidity remains strong with $4B+ in revolving credit capacity, though the debt/equity ratio of 0.8 suggests moderate financial leverage for the sector.
Organic revenue growth has averaged 7% annually since 2020, outpacing medtech peers. The dividend was raised to $3.20/share (1.7% yield), with a conservative 40% payout ratio allowing reinvestment in growth initiatives. Share repurchases totaled $1.5B in FY2024, reducing shares outstanding by 1.5% to 381M. Procedure volume recovery post-pandemic and international expansion (35% of sales) provide multi-year tailwinds.
Trading at ~25x forward P/E, Stryker commands a premium to the S&P 500, reflecting its durable growth profile and margin expansion potential. The market prices in 6-8% annual revenue growth through 2026, with EPS growth accelerating to 10%+ as Mako robotics adoption reaches critical mass in international markets and operating efficiencies materialize.
Stryker's installed base of 1,500+ Mako systems creates recurring revenue streams through disposables and software upgrades. Regulatory moats around its 17,000 patents and hospital contracting bundling strategies limit competitive threats. Guidance suggests 200-300bps of annual operating margin improvement through 2026 via supply chain optimization and mix shift toward higher-margin capital equipment.
Company 10-K, Investor Presentations, Bloomberg Intelligence
show cash flow forecast
Fiscal year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
Revenue growth rate, % | NaN | |||||||||||||||||||||||||
Revenue, $ | NaN | |||||||||||||||||||||||||
Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
Total operating expenses, $m | NaN | |||||||||||||||||||||||||
Operating income, $m | NaN | |||||||||||||||||||||||||
EBITDA, $m | NaN | |||||||||||||||||||||||||
Interest expense (income), $m | NaN | |||||||||||||||||||||||||
Earnings before tax, $m | NaN | |||||||||||||||||||||||||
Tax expense, $m | NaN | |||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
Total assets, $m | NaN | |||||||||||||||||||||||||
Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
Average production assets, $m | NaN | |||||||||||||||||||||||||
Working capital, $m | NaN | |||||||||||||||||||||||||
Total debt, $m | NaN | |||||||||||||||||||||||||
Total liabilities, $m | NaN | |||||||||||||||||||||||||
Total equity, $m | NaN | |||||||||||||||||||||||||
Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
Funds from operations, $m | NaN | |||||||||||||||||||||||||
Change in working capital, $m | NaN | |||||||||||||||||||||||||
Cash from operations, $m | NaN | |||||||||||||||||||||||||
Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
New CAPEX, $m | NaN | |||||||||||||||||||||||||
Total CAPEX, $m | NaN | |||||||||||||||||||||||||
Free cash flow, $m | NaN | |||||||||||||||||||||||||
Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
Discount rate, % | NaN | |||||||||||||||||||||||||
PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
Current shareholders' claim on cash, % | NaN |